Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes

Ikram Ullah, Govindasamy-Muralidharan Karthik, Amjad Alkodsi, Una Kjällquist, Gustav Stålhammar, John Lövrot, Nelson-Fuentes Martinez, Jens Lagergren, Sampsa Hautaniemi, Johan Hartman, Jonas BerghJournal of Clinical Investigation 2018 · DOI

Abstract

Metastatic breast cancers are still incurable. Characterizing the evolutionary landscape of these cancers, including the role of metastatic axillary lymph nodes (ALNs) in seeding distant organ metastasis, can provide a rational basis for effective treatments. Here, we have described the genomic analyses of the primary tumors and metastatic lesions from 99 samples obtained from 20 patients with breast cancer. Our evolutionary analyses revealed diverse spreading and seeding patterns that govern tumor progression. Although linear evolution to successive metastatic sites was common, parallel evolution from the primary tumor to multiple distant sites was also evident. Metastatic spreading was frequently coupled with polyclonal seeding, in which multiple metastatic subclones originated from the primary tumor and/or other distant metastases. Synchronous ALN metastasis, a well-established prognosticator of breast cancer, was not involved in seeding the distant metastasis, suggesting a hematogenous route for cancer dissemination. Clonal evolution coincided frequently with emerging driver alterations and evolving mutational processes, notably an increase in apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like-associated (APOBEC-associated) mutagenesis. Our data provide genomic evidence for a role of ALN metastasis in seeding distant organ metastasis and elucidate the evolving mutational landscape during cancer progression.

Introduction: The Pathway of Metastasis

For decades, oncology has debated how breast cancer moves through the body. The classical "Halstedian" view suggests a linear progression: the tumor spreads first to the regional axillary lymph nodes (ALNs) and then moves on to distant organs like the lungs or bones. Conversely, the "Fisherian" view posits that cancer is a systemic disease from the start, and lymph nodes are merely indicators of a tumor's aggressive potential, not the source of further spread.

Understanding this pathway is critical for clinical decision-making. If lymph nodes are active "way stations," their removal is curative; if they are passive markers, surgery might be over-treatment. This study uses high-resolution genomic sequencing to provide robust evidence of whether ALNs actually seed distant metastases.

Methods and Cohort Description

The research team performed whole-exome sequencing (WES) on 99 tumor samples and matched normal controls from a longitudinal cohort of 20 patients. To map the cancer's journey, they employed several sophisticated computational tools, including phylogenetic reconstruction using Dollo parsimony and subclonal analysis via PyClone. This allowed them to identify different "families" of cells within a single tumor and see which specific groups were responsible for seeding new sites.

Cohort selection and sample distribution across patients and metastatic sites.

A mathematical approach called the "separating property" was used on the phylogenetic trees to determine if a distant metastasis was more likely seeded by the primary tumor (parallel evolution) or a previous metastasis (linear evolution).

Key Results: Evolutionary Patterns and the Role of ALNs

The study found that synchronous ALN metastasis, while a strong prognostic marker, was rarely involved in seeding distant metastases. In 8 patients where both ALNs and distant metastases were sequenced, the probability that the ALN seeded the distant site was near zero in almost every case. This supports the "speedometer" analogy: positive lymph nodes indicate aggressive disease (high speed), but removing them doesn't necessarily stop the spread (slowing the car).

Evolutionary patterns were found to be diverse across the cohort. In some patients, the primary tumor seeded multiple distant sites independently (parallel spread), while in others, one metastasis seeded another (linear spread). Polyclonal seeding was the norm, observed in 73% of cases, where multiple subclones from the primary tumor or other metastases traveled together to colonize new organs.

Phylogenetic trees for four patients illustrating diverse metastatic spreading patterns and subclonal evolution.

The mutational landscape also evolved significantly. Metastatic lesions showed an increase in APOBEC-associated mutagenesis, suggesting this process provides the "mutational fuel" for cancer cells to adapt to new environments. While early driver mutations (e.g., TP53, PIK3CA) were ubiquitous, late drivers (e.g., BRCA2, ESR1) often emerged only in metastatic sites, likely under therapeutic pressure.

Discussion and Future Directions

The findings suggest a predominantly hematogenous route for distant dissemination rather than a lymphatic one. This has significant implications for how we view the role of regional lymph nodes in breast cancer progression.

Primary limitations include the small sample size (20 patients) and the use of bulk sequencing, which, while powerful, may not capture the full resolution of individual "seed" cells. Future research using single-cell sequencing and liquid biopsies to monitor evolutionary "drift" in real-time will be essential to further refine these models and improve clinical outcomes.

Summary updated

Abstract

Metastatic breast cancers are still incurable. Characterizing the evolutionary landscape of these cancers, including the role of metastatic axillary lymph nodes (ALNs) in seeding distant organ metastasis, can provide a rational basis for effective treatments. Here, we have described the genomic analyses of the primary tumors and metastatic lesions from 99 samples obtained from 20 patients with breast cancer. Our evolutionary analyses revealed diverse spreading and seeding patterns that govern tumor progression. Although linear evolution to successive metastatic sites was common, parallel evolution from the primary tumor to multiple distant sites was also evident. Metastatic spreading was frequently coupled with polyclonal seeding, in which multiple metastatic subclones originated from the primary tumor and/or other distant metastases. Synchronous ALN metastasis, a well-established prognosticator of breast cancer, was not involved in seeding the distant metastasis, suggesting a hematogenous route for cancer dissemination. Clonal evolution coincided frequently with emerging driver alterations and evolving mutational processes, notably an increase in apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like-associated (APOBEC-associated) mutagenesis. Our data provide genomic evidence for a role of ALN metastasis in seeding distant organ metastasis and elucidate the evolving mutational landscape during cancer progression.
BibTeX
@article{ullah2018evolutionary,
  author = {Ikram Ullah and Govindasamy-Muralidharan Karthik and Amjad Alkodsi and Una Kjällquist and Gustav Stålhammar and John Lövrot and Nelson-Fuentes Martinez and Jens Lagergren and Sampsa Hautaniemi and Johan Hartman and Jonas Bergh},
  title = {{Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes}},
  journal = {Journal of Clinical Investigation},
  year = {2018},
  doi = {10.1172/jci96149},
}
Figure